Jones Trading initiates Beam Therapeutics stock coverage with buy rating
Jones Trading initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and $35 price target. The stock trades at $27.79, with analysts' targets ranging from $26 to $80. The firm forecasts $3.2B peak sales for BEAM-302 by 2034. Beam reported Q2 2026 results, dosing the first patient in a pivotal trial for AATD. H.C. Wainwright reiterated its Buy rating with an $80 target.
How this was made
The 30-second read
Why it matters
The initiation and $35 target could attract new buying interest, potentially lifting the stock toward the target range.
Market read
First‑time analyst coverage with a concrete price target provides a clear trading signal for BEAM.
What to watch
Regulatory timelines and competition in the AATD space may limit upside despite the bullish target.
Background
Beam Therapeutics is a CRISPR‑based gene‑editing company with several late‑stage programs. The new coverage adds a fresh analyst perspective.
Ticker impact
Jones Trading initiates coverage on Beam Therapeutics with a Buy rating and a $35 price target, a first‑time analyst recommendation.
likely upward pressure as investors price in the new $35 target versus current $27.79 price
The coverage is fresh, includes a concrete price target above current levels, and highlights a pipeline with long‑term revenue potential, prompting buy‑side interest.
Market effects
Positive sentiment may spill over to other gene‑editing and biotech stocks as the coverage highlights a promising pipeline.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance, primarily affecting U.S. biotech and specialty pharma investors.
Counterpoint
The valuation assumes high success probabilities for multiple programs; failure or delays could pressure the stock.
Key entities
- AnalystJones Trading
Initiated coverage with a Buy rating and $35 price target.
- CompanyBeam Therapeutics Inc
Biotech firm developing CRISPR therapies, subject of the new coverage.
